Biotech entity
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Alltrna, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 3.6 for the same window.
Last mentioned: Mar 12, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Alltrna, the most common co-covered peer. They are less corroborated than the beat average, carrying 2 original sources each against 3.6 for the same window. At 5, the average consequence score sits below the same-window beat average of 6. We currently track 1 Biotech story that mention Michelle C. Werner, all published on March 12, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 22 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Michelle C. Werner. Shared-story counts are live from our verified record — not editorial picks.
Ipsen has appointed Michelle C. Werner as Executive Vice President and President of North America, effective March 2026. A veteran of AstraZeneca and former CEO of Alltrna, Werner is tasked with accelerating growth in Ipsen's largest market across its oncology, rare disease, and neuroscience portfolios.
Michelle C. Werner is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
